QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s…